109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
乌帕替尼成功治疗难治性网状血管炎：一例报告
Authors Wang C, Wang X, He P, Tao X , Liu W
Received 29 July 2025
Accepted for publication 4 October 2025
Published 13 October 2025 Volume 2025:18 Pages 2645—2650
DOI https://doi.org/10.2147/CCID.S556844
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Jeffrey Weinberg
Cuiqin Wang,1– 5,* Xiaobing Wang,1– 5,* Pingxiu He,1– 5 Xiaohua Tao,1– 5 Weijun Liu1– 5
1Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People’s Republic of China; 2Department of Dermatology, Jiangxi Provincial Clinical Research Center for Skin Diseases, Nanchang, Jiangxi, People’s Republic of China; 3Department of Dermatology, Candidate Branch of National Clinical Research Center for Skin Diseases, Nanchang, Jiangxi, People’s Republic of China; 4Department of Dermatology, Dermatology Institute of Jiangxi Province, Nanchang, Jiangxi, People’s Republic of China; 5Department of Dermatology, The Affiliated Dermatology Hospital of Nanchang University, Nanchang, Jiangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weijun Liu; Xiaohua Tao, Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, 330001, People’s Republic of China, Tel +86 15180151935, Fax +86-0791-85207512, Email liuweijun104@163.com; taoxiaohua@126.com
Purpose: While tofacitinib, baricitinib, and abrocitinib demonstrate efficacy in livedoid vasculopathy (LV), this study evaluates upadacitinib—a distinct Janus kinase (JAK) inhibitor—in refractory LV.
Patients and Methods: A 54-year-old female with treatment-resistant LV received upadacitinib (15 mg/day). Treatment response was assessed via composite clinical scores pre- and post-therapy.
Results: Significant improvement occurred within 24 days (score: 7→ 2), indicating remission. Pain intensity markedly decreased, and near-complete ulcer healing was observed by day 52. No adverse effects were observed, with the exception of orolabial herpes simplex.
Conclusion: Upadacitinib represents a novel therapeutic alternative for LV. Larger cohorts are needed to validate these findings.
Keywords: livedoid vasculopathy, upadacitinib, JAK inhibitor
1Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People’s Republic of China; 2Department of Dermatology, Jiangxi Provincial Clinical Research Center for Skin Diseases, Nanchang, Jiangxi, People’s Republic of China; 3Department of Dermatology, Candidate Branch of National Clinical Research Center for Skin Diseases, Nanchang, Jiangxi, People’s Republic of China; 4Department of Dermatology, Dermatology Institute of Jiangxi Province, Nanchang, Jiangxi, People’s Republic of China; 5Department of Dermatology, The Affiliated Dermatology Hospital of Nanchang University, Nanchang, Jiangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weijun Liu; Xiaohua Tao, Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, 330001, People’s Republic of China, Tel +86 15180151935, Fax +86-0791-85207512, Email liuweijun104@163.com; taoxiaohua@126.com
Purpose: While tofacitinib, baricitinib, and abrocitinib demonstrate efficacy in livedoid vasculopathy (LV), this study evaluates upadacitinib—a distinct Janus kinase (JAK) inhibitor—in refractory LV.
Patients and Methods: A 54-year-old female with treatment-resistant LV received upadacitinib (15 mg/day). Treatment response was assessed via composite clinical scores pre- and post-therapy.
Results: Significant improvement occurred within 24 days (score: 7→ 2), indicating remission. Pain intensity markedly decreased, and near-complete ulcer healing was observed by day 52. No adverse effects were observed, with the exception of orolabial herpes simplex.
Conclusion: Upadacitinib represents a novel therapeutic alternative for LV. Larger cohorts are needed to validate these findings.
Keywords: livedoid vasculopathy, upadacitinib, JAK inhibitor